Tipifarnib

Penn State College of Medicine, Beat Childhood Cancer Research Consortium, and Four Diamonds are launching a clinical trial to test a new drug combination for relapsed and refractory neuroblastoma, involving tipifarnib and naxitamab. The trial aims to improve treatment outcomes for children with neuroblastoma by enhancing the efficacy of immunotherapy.

Kura Oncology to participate in JMP Securities Hematology and Oncology Summit on Dec 2, 2024. The company is focused on precision medicines for cancer treatment, with ziftomenib as a key drug candidate.

Kura Oncology secures $330 million from Kyowa Kirin for ziftomenib, a menin inhibitor targeting KMT2A-mutated leukemia, with plans for FDA submission in 2025. The collaboration aims to develop ziftomenib across leukemias and solid tumors, with potential milestone payments up to $1.2 billion.

JMP Securities' Reni Benjamin maintains Buy rating on Kura Oncology (KURA) with $32.00 price target, citing KOMET-001 study results expected in 2025, breakthrough designation for Zifto in NPM1-m AML, strong cash position, and upcoming data presentations.

Kura Oncology to report Q3 2024 financial results on Nov 7, 2024, with a webcast and conference call at 4:30 p.m. ET / 1:30 p.m. PT. The call can be accessed via phone or webcast on the company's website.

Kura Oncology appoints Michael Vasconcelles, M.D., to its Board of Directors. Dr. Vasconcelles brings over 25 years of oncology drug development experience and leadership. He is currently a Senior Advisor at Frazier Healthcare Partners and has held senior roles at ImmunoGen, Flatiron Health, Unum Therapeutics, Takeda/Millennium, and Genzyme Corporation. Dr. Vasconcelles expressed enthusiasm for Kura's precision oncology approach and its menin inhibitor program for acute leukemias.

Kura Oncology (KURA) is a clinical-stage biopharmaceutical company developing precision medicines for cancer, with key candidates like Tipifarnib, Ziftomenib, and KO-2806. Recent achievements include preliminary data from the KOMET-007 trial and securing financing through 2027.